Clinical trialNCT04001517CompletedPhase 2Interventional

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

SponsorEIP Pharma IncEnrollment91Dementia With Lewy Bodies (DLB)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

John Alam, MD
EIP Pharma
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Netherlands

Brain Research Center
's-Hertogenbosch, Netherlands
Brain Research Center
Amsterdam, Netherlands

United States

University of California San Diego (ucsd)
La Jolla, California, United States
Pacific Neuroscience Institute
Santa Monica, California, United States
University of Colorado
Aurora, Colorado, United States
Elite Clinical Research
Miami, Florida, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Massachusetts General Hospital
Charlestown, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Cleveland Clinic - Lou Ruvo Center for Brain Health
Las Vegas, Nevada, United States
New York Presbyterian Hospital - Columbia University Medical Center
New York, New York, United States
University of Rochester
Rochester, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
the Ohio State University
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Summit Research Network
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Virginia
Charlottesville, Virginia, United States
National Clinical Research, Inc.
Richmond, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
University of Washington
Seattle, Washington, United States
Inland Northwest Research
Spokane, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Neflamapimod

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2019
Primary completion: 30 Jun 2020
Completion: 30 Jun 2020
Last update posted: 29 Jun 2023
Registered enrollment: 91
Registry id: NCT04001517

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.